Natalizumab
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1) . Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses[1].
Product Specifications
CAS Number
[189261-10-7]
UNSPSC
12352203
Target
Integrin
Type
Inhibitory Antibodies
Related Pathways
Cytoskeleton
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/natalizumab.html
Purity
99.10
Solubility
H2O
Smiles
[Natalizumab]
Molecular Weight
(146.19 kDa)
References & Citations
[1]Hutchinson M. Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007 Jun;3 (2) :259-68.
Shipping Conditions
Isolate blue ice and the product with bubble pack to avoid direct contact
Storage Conditions
Store at 4°C for 2 years, do not freeze
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Isoform
α4β1
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
